Improving drug discovery with high-content phenotypic screens by systematic selection of reporter cell lines

High-content, image-based screens enable the identification of compounds that induce cellular responses similar to those of known drugs but through different chemical structures or targets. A central challenge in designing phenotypic screens is choosing suitable imaging biomarkers. Here we present a method for systematically identifying optimal reporter cell lines for annotating compound libraries (ORACLs), whose phenotypic profiles most accurately classify a training set of known drugs. We generate a library of fluorescently tagged reporter cell lines, and let analytical criteria determine which among them—the ORACL—best classifies compounds into multiple, diverse drug classes. We demonstrate that an ORACL can functionally annotate large compound libraries across diverse drug classes in a single-pass screen and confirm high prediction accuracy by means of orthogonal, secondary validation assays. Our approach will increase the efficiency, scale and accuracy of phenotypic screens by maximizing their discriminatory power.

[1]  R. Milo,et al.  Dynamic Proteomics of Individual Cancer Cells in Response to a Drug , 2008, Science.

[2]  C. Bakal,et al.  Quantitative Morphological Signatures Define Local Signaling Networks Regulating Cell Morphology , 2007, Science.

[3]  Anne E Carpenter,et al.  Multiplex Cytological Profiling Assay to Measure Diverse Cellular States , 2013, PloS one.

[4]  Masashi Sugiyama,et al.  Dimensionality Reduction of Multimodal Labeled Data by Local Fisher Discriminant Analysis , 2007, J. Mach. Learn. Res..

[5]  Lawrence Lum,et al.  Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer , 2008, Nature chemical biology.

[6]  M. Kuwano,et al.  Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. , 2004, Molecular cancer therapeutics.

[7]  Walter Kolch,et al.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer , 2010, Nature Reviews Cancer.

[8]  Anne E Carpenter,et al.  Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling , 2014, Proceedings of the National Academy of Sciences.

[9]  John G. Moffat,et al.  Phenotypic screening in cancer drug discovery — past, present and future , 2014, Nature Reviews Drug Discovery.

[10]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[11]  Anne E Carpenter,et al.  Dynamic proteomics in individual human cells uncovers widespread cell-cycle dependence of nuclear proteins , 2006, Nature Methods.

[12]  Christopher P Austin,et al.  High-throughput screening assays for the identification of chemical probes. , 2007, Nature chemical biology.

[13]  Charles E. Heckler,et al.  Applied Multivariate Statistical Analysis , 2005, Technometrics.

[14]  Todd R Golub,et al.  Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation , 2004, Nature Genetics.

[15]  C. Sigman,et al.  Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.

[16]  Neil O Carragher,et al.  High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells , 2010, Molecular Cancer Therapeutics.

[17]  David R. Spring,et al.  Diversity-Oriented Synthesis: Producing Chemical Tools for Dissecting Biology , 2012 .

[18]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[19]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[20]  J. Lamerdin,et al.  Identifying off-target effects and hidden phenotypes of drugs in human cells , 2006, Nature chemical biology.

[21]  C. Teng,et al.  The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells , 2013, Cell Death and Disease.

[22]  Julian L. Griffin,et al.  Metabolic profiles of cancer cells , 2004, Nature Reviews Cancer.

[23]  G. Klebe.  Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[24]  Stuart L Schreiber,et al.  Towards the optimal screening collection: a synthesis strategy. , 2008, Angewandte Chemie.

[25]  K. Strimmer,et al.  Statistical Applications in Genetics and Molecular Biology A Shrinkage Approach to Large-Scale Covariance Matrix Estimation and Implications for Functional Genomics , 2011 .

[26]  S A Sundberg,et al.  High-throughput and ultra-high-throughput screening: solution- and cell-based approaches. , 2000, Current opinion in biotechnology.

[27]  S. Omholt,et al.  Phenomics: the next challenge , 2010, Nature Reviews Genetics.

[28]  Frank E Koehn,et al.  High impact technologies for natural products screening. , 2008, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[29]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[30]  A. Kudlicki,et al.  Valosin-containing protein (p97) is a regulator of endoplasmic reticulum stress and of the degradation of N-end rule and ubiquitin-fusion degradation pathway substrates in mammalian cells. , 2006, Molecular biology of the cell.

[31]  S. Demo,et al.  Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. , 2005, Blood.

[32]  David R Spring,et al.  Diversity-oriented synthesis: producing chemical tools for dissecting biology. , 2012, Chemical Society reviews.

[33]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[34]  Trey Ideker,et al.  Using Functional Signature Ontology (FUSION) to Identify Mechanisms of Action for Natural Products , 2013, Science Signaling.

[35]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[36]  Lani F. Wu,et al.  Multidimensional Drug Profiling By Automated Microscopy , 2004, Science.

[37]  Andrew Smellie,et al.  Identification of a Small Molecule That Induces Mitotic Arrest Using a Simplified High-Content Screening Assay and Data Analysis Method , 2006, Journal of biomolecular screening.

[38]  M. Boutros,et al.  Clustering phenotype populations by genome-wide RNAi and multiparametric imaging , 2010, Molecular systems biology.

[39]  H. Osada,et al.  Morphobase, an encyclopedic cell morphology database, and its use for drug target identification. , 2012, Chemistry & biology.

[40]  D Lansing Taylor,et al.  Past, present, and future of high content screening and the field of cellomics. , 2007, Methods in molecular biology.

[41]  N. Gray,et al.  Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.

[42]  John A. Tallarico,et al.  Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.

[43]  P. Vernier,et al.  Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques , 1997, Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques.

[44]  C. Dinarello,et al.  Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Chang-Young Jang,et al.  Interaction of Hsp90 with ribosomal proteins protects from ubiquitination and proteasome-dependent degradation. , 2005, Molecular biology of the cell.

[46]  Vogel,et al.  Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques , 1990, Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques.

[47]  K. Stegmaier,et al.  Genetic and proteomic approaches to identify cancer drug targets , 2011, British Journal of Cancer.

[48]  Di Chen,et al.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. , 2011, Current cancer drug targets.

[49]  Lorenz M Mayr,et al.  Novel trends in high-throughput screening. , 2009, Current opinion in pharmacology.

[50]  S. Kimura,et al.  Identification of a small-molecule inhibitor of DNA topoisomerase II by proteomic profiling. , 2011, Chemistry & biology.

[51]  Jun Wu,et al.  Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase , 2010, Acta Pharmacologica Sinica.

[52]  Robert F. Murphy,et al.  Efficient discovery of responses of proteins to compounds using active learning , 2013, BMC Bioinformatics.

[53]  John A. Tallarico,et al.  Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds , 2009, Nature Reviews Drug Discovery.

[54]  Makoto Muroi,et al.  Application of proteomic profiling based on 2D-DIGE for classification of compounds according to the mechanism of action. , 2010, Chemistry & biology.

[55]  Mehmet Toner,et al.  A high-throughput microfluidic real-time gene expression living cell array. , 2007, Lab on a chip.

[56]  Christine J. Martin,et al.  Molecular characterization of macbecin as an Hsp90 inhibitor. , 2008, Journal of medicinal chemistry.

[57]  Stefan Wetzel,et al.  Charting, navigating, and populating natural product chemical space for drug discovery. , 2012, Journal of medicinal chemistry.

[58]  Lani F. Wu,et al.  Image-based multivariate profiling of drug responses from single cells , 2007, Nature Methods.